Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase III clinical trials for the treatment of acromegaly, an orphan disease. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.